PROELITE, INC. - FORM SC 13D Filed by ISAAC BLECH

PROELITE, INC. - FORM SC 13D Filed by ISAAC BLECH ( Statement of Beneficial Ownership) of 165,568,000 shares of Common Stock that will become exercisable by the Reporting Person on September 10, 2012.

http://www.otcmarkets.com/edgar/GetFilingPdf?...ID=8720394

Mr. Isaac Blech is the Founder of Cerecor, Inc. Over the past three decades, Isaac Blech established some of the leading biotechnology companies in the world. These include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation, and Genetics Systems Corporation with a combined value in excess of $30 billion. Celgene Corporation introduced two major cancer drugs, and has a current value of over $25 billion. ICOS Corporation discovered the drug Cialis, and was acquired by Eli Lilly for over $2 billion. Nova Pharmaceutical Corporation developed a new treatment for brain cancer, and after merging with Scios Corporation, was purchased for $2 billion. Pathogeneses Corporation created TOBI for cystic fibrosis, the first inhaled antibiotic approved by the Food and Drug Administration, and was acquired by Chiron Corp for $660 million. Genetics Systems developed the first inexpensive and accurate test to diagnosis chlamydia, allowing thousands of babies to be born to women who otherwise would have become sterile from pelvic inflammatory disease. Genetics Systems was acquired for 3% of Bristol Myers' stock. Mr. Blech is currently a major shareholder and board member of ContraFect Corporation which is creating new therapies for infectious diseases, and is on the Strategic Advisory Board of Medgenics.

He has been Vice Chairman at BillMyParents, Inc. since November 1, 2011. He has been a Director of Premier Alliance Group Inc. since June 2011. Mr. Blech has been a Director of Medgenics, Inc. since June 2011. He has been a Director of BillMyParents, Inc. since March 10, 2011. He serves as Member of the Board of Directors at Cerecor, Inc. He serves as a Director of ContraFect Corporation. He served on the board of several companies for over 30 years. He served as a Member of Strategic Advisory Board of Medgenics, Inc. since February 2011. Mr. Blech is a renowned biotechnology industry Investor. Mr. Blech earned a BA. degree from Baruch College in 1975.